109.35
price up icon0.88%   0.95
 
loading
Schlusskurs vom Vortag:
$108.40
Offen:
$109.86
24-Stunden-Volumen:
1.10M
Relative Volume:
1.03
Marktkapitalisierung:
$219.52B
Einnahmen:
$49.94B
Nettoeinkommen (Verlust:
$17.60B
KGV:
29.40
EPS:
3.72
Netto-Cashflow:
$12.51B
1W Leistung:
-3.90%
1M Leistung:
-4.54%
6M Leistung:
+12.15%
1J Leistung:
+16.01%
1-Tages-Spanne:
Value
$109.30
$110.03
1-Wochen-Bereich:
Value
$107.94
$115.77
52-Wochen-Spanne:
Value
$92.35
$120.92

Novartis Ag Adr Stock (NVS) Company Profile

Name
Firmenname
Novartis Ag Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
76,057
Name
Twitter
@novartis
Name
Nächster Verdiensttermin
2024-10-29
Name
Neueste SEC-Einreichungen
Name
NVS's Discussions on Twitter

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-05 Herabstufung Goldman Buy → Neutral
2024-09-03 Herabstufung Jefferies Buy → Hold
2024-07-19 Herabstufung Deutsche Bank Buy → Hold
2024-05-30 Eingeleitet Goldman Buy
2024-02-23 Eingeleitet BMO Capital Markets Market Perform
2024-01-23 Eingeleitet Morgan Stanley Equal-Weight
2024-01-16 Fortgesetzt UBS Buy
2023-12-18 Herabstufung HSBC Securities Buy → Hold
2023-09-25 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-26 Hochstufung Deutsche Bank Hold → Buy
2023-03-27 Hochstufung Deutsche Bank Sell → Hold
2023-01-26 Herabstufung Citigroup Buy → Neutral
2022-12-05 Hochstufung Stifel Hold → Buy
2022-09-15 Herabstufung Credit Suisse Neutral → Underperform
2022-09-14 Herabstufung Berenberg Buy → Hold
2022-05-09 Herabstufung Wolfe Research Outperform → Peer Perform
2022-01-10 Fortgesetzt Citigroup Buy
2021-12-14 Herabstufung Redburn Buy → Neutral
2021-12-06 Herabstufung Exane BNP Paribas Outperform → Neutral
2021-12-03 Herabstufung Bryan Garnier Buy → Neutral
2021-09-20 Herabstufung Deutsche Bank Hold → Sell
2021-03-22 Eingeleitet Bernstein Mkt Perform
2021-03-10 Herabstufung Argus Buy → Hold
2021-02-01 Herabstufung Cowen Outperform → Market Perform
2021-01-15 Eingeleitet Deutsche Bank Buy
2020-09-29 Eingeleitet Berenberg Buy
2020-09-10 Hochstufung UBS Neutral → Buy
2020-09-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-06-15 Hochstufung Citigroup Neutral → Buy
2020-03-10 Hochstufung Morgan Stanley Underweight → Equal-Weight
2020-02-25 Herabstufung Guggenheim Buy → Neutral
2019-04-25 Hochstufung Guggenheim Neutral → Buy
2019-04-25 Hochstufung Liberum Hold → Buy
2019-04-10 Herabstufung Morgan Stanley Equal-Weight → Underweight
2019-01-02 Herabstufung JP Morgan Neutral → Underweight
2018-12-11 Fortgesetzt Jefferies Buy
2018-10-09 Eingeleitet Guggenheim Neutral
2018-09-10 Hochstufung BofA/Merrill Underperform → Buy
2018-05-29 Herabstufung HSBC Securities Buy → Hold
2018-05-25 Hochstufung Credit Suisse Underperform → Neutral
2018-01-25 Bestätigt Leerink Partners Outperform
2017-12-06 Herabstufung BofA/Merrill Neutral → Underperform
2017-07-26 Hochstufung Morgan Stanley Underweight → Overweight
2017-07-05 Herabstufung Credit Suisse Neutral → Underperform
2017-03-09 Eingeleitet Liberum Buy
Alle ansehen

Novartis Ag Adr Aktie (NVS) Neueste Nachrichten

pulisher
Nov 01, 2024

Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis

Nov 01, 2024
pulisher
Oct 29, 2024

Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar

Oct 29, 2024
pulisher
Oct 29, 2024

Chemical Biology in Biomedical Research - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Radioligand therapy: delivering now, building for the future - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis Financial Results – Q2 2024 - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Inclusivity - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Collaborations - Novartis

Oct 29, 2024
pulisher
Oct 26, 2024

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial - GlobeNewswire Inc.

Oct 26, 2024
pulisher
Oct 25, 2024

Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.

Oct 25, 2024
pulisher
Oct 23, 2024

Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance

Oct 23, 2024
pulisher
Oct 22, 2024

5 Large Drug Stocks Likely To Outpace Q3 Earnings Estimates - Barchart

Oct 22, 2024
pulisher
Oct 18, 2024

21 Best Healthcare Companies to Invest In - Morningstar

Oct 18, 2024
pulisher
Oct 17, 2024

1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move - sharewise

Oct 17, 2024
pulisher
Oct 16, 2024

Saudi Arabia Generic Pharmaceutical Products Market Report 2024-2031, Featuring Profiles of Key Players - GlobeNewswire Inc.

Oct 16, 2024
pulisher
Oct 15, 2024

Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.

Oct 15, 2024
pulisher
Oct 14, 2024

Roche Wins FDA Nod For Breast Cancer Drug In First-Line Setting - Barchart

Oct 14, 2024
pulisher
Oct 11, 2024

Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 11, 2024
pulisher
Oct 09, 2024

Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 09, 2024
pulisher
Oct 09, 2024

Norway Aspergillosis Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 09, 2024
pulisher
Oct 07, 2024

Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine

Oct 07, 2024
pulisher
Oct 01, 2024

NVS: 3 European Stocks to Watch as the EU Economy Strengthens - StockNews.com

Oct 01, 2024
pulisher
Sep 25, 2024

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-term Growth - Morningstar

Sep 25, 2024
pulisher
Sep 21, 2024

Europe Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research

Sep 21, 2024
pulisher
Sep 20, 2024

Australia Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research

Sep 20, 2024
pulisher
Sep 18, 2024

Novartis Wins FDA Approval Of Kisqali For Early Breast Cancer - Barchart

Sep 18, 2024
pulisher
Sep 17, 2024

Novartis' Kisqali Lowers Risk Of Breast Cancer Recurrence By 28% - Barchart

Sep 17, 2024
pulisher
Sep 17, 2024

North America Immune Health Supplements Market Size & Outlook, 2030 - Grand View Research

Sep 17, 2024
pulisher
Sep 16, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Sep 16, 2024
pulisher
Sep 12, 2024

Top investors say Novartis AG ADR (NVS) ticks everything they need - SETE News

Sep 12, 2024
pulisher
Sep 11, 2024

Novartis lower as BofA downgrades on risks to valuation - MSN

Sep 11, 2024
pulisher
Sep 09, 2024

Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.

Sep 09, 2024
pulisher
Sep 05, 2024

Morgan Stanley cuts Novartis rating amid limited innovation - Baystreet.ca

Sep 05, 2024
pulisher
Sep 04, 2024

Spain Congestive Heart Failure Drugs Market Size & Outlook, 2030 - Grand View Research

Sep 04, 2024
pulisher
Sep 04, 2024

Market Insight: Novartis AG ADR (NVS)’s Notable Drop, Closing at 118.50 - The Dwinnex

Sep 04, 2024
pulisher
Sep 03, 2024

Canada Cell And Gene Therapy CDMO Market Size & Outlook, 2030 - Grand View Research

Sep 03, 2024
pulisher
Sep 03, 2024

The United States Erythropoietin Drugs Market Size & Outlook, 2030 - Grand View Research

Sep 03, 2024
pulisher
Sep 03, 2024

China Biotechnology Market Size & Outlook, 2023-2030 - Grand View Research

Sep 03, 2024
pulisher
Sep 03, 2024

Kuwait Gout Therapeutics Market Size & Outlook, 2023-2030 - Grand View Research

Sep 03, 2024

Finanzdaten der Novartis Ag Adr-Aktie (NVS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$319.22
price down icon 0.29%
drug_manufacturers_general PFE
$28.09
price down icon 0.74%
drug_manufacturers_general MRK
$101.88
price down icon 0.43%
drug_manufacturers_general SNY
$53.27
price up icon 0.74%
$89.51
price up icon 0.78%
Kapitalisierung:     |  Volumen (24h):